MELBOURNE, AUSTRALIA: Starpharma Holdings (ASX: SPL) announced the appointment of Ms Cheryl Maley as Chief Executive Officer (CEO) and Managing Director of Starpharma effective 8 January 2024. Cheryl has over 25 years of experience in the pharmaceutical industry, including 20 years in leadership roles at well-known and leading organisations, including Novartis and AbbVie/Abbott. Her roles…
MELBOURNE: Starpharma Holdings has signed a Research Agreement with MSD, the tradename of Merck & Co., Inc., Kenilworth NJ USA. Under the agreement, MSD will conduct a preclinical research evaluation of dendrimer based Antibody Drug Conjugates (ADCs) utilising Starpharma’s proprietary DEP technology. Dr Jackie Fairley, CEO of Starpharma commented: “MSD is a recognised leader in…
MELBOURNE: Starpharma Holdings Limited announced that following the successful launch of the VivaGel antiviral condom by Okamoto Industries in Japan, Okamoto has sought an expansion to its licence territory for the VivaGel condom. As a result, Starpharma has granted Okamoto marketing rights to a further 11 countries in Asia which include South Korea, Indonesia, Malaysia,…